Comparison of Peganum harmala L. leaves extract nanoformulations against herpes simplex virus type 1 guided by network pharmacology analysis

Résumé

Abstract Herpes simplex virus type 1 (HSV-1) is a highly prevalent viral infection with limited medications. Thus, search for safe and effective alternative treatments is urgently needed. Peganum harmala L. ( P. harmala ) praised with antiviral potential may afford a decent option against HSV-1. This study creatively integrated network pharmacology and nanoscience to objectively disclose the efficacy mechanism of P. harmala bioactive compounds and augment the antiviral potential of P. harmala against HSV-1 via nanotechnology. Network pharmacology analysis revealed MAPK 1, SRC, EGFR and JAK1 as the top putative HSV-1 genes highly enriched in MAPK, PI3K-Akt, and JAK-STAT signalling pathways and primarily associated with the efficacy mechanism of P. harmala bioactive compounds against HSV-1. Complementarily, four P. harmala nano-formulations were established, monitored using different pharmaceutical scores, and assessed against HSV-1 using plaque reduction assay. Experimentally speaking, P. harmala -CS-ZnO NPs showed higher zeta (+ 40.8) with particle-size (73.06 nm), higher entrapment (81.7%) with loading-capacity (6.8%), sustained release reaching 50.5% after 24 h and demonstrated the most promising observation against HSV-1, with viral inhibition of 54.1% which is double the effect of crude extract alone with acceptable cytotoxicity (CC 50 = 271.4 µg/ml). This enhanced effect is possibly due to the synergistic antiviral properties of P. harmala bioactive compounds, chitosan, and zinc oxide nanoparticles. This complex between the ingredients chemically detected by FT-IR analysis also improved stability, cellular uptake, viral inhibition, and bioavailability. Our findings offer a solid basis for more extensive and rational clinical integration of P. harmala in the pharmaceutical industry to rectify human herpes viruses.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0